Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lepidoglyphus destructor extract
- Development stage
- Phase 3
- Lead developer
- Inmunotek
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Sublingual, Subcutaneous
01
Overview
Lepidoglyphus destructor extract is a biological allergen preparation developed by Inmunotek S.L. for the treatment of Type I hypersensitivity reactions to the storage mite *Lepidoglyphus destructor*. Commonly found in agricultural settings and stored food products, this mite is a significant trigger for allergic rhinitis and asthma. The extract is used in allergen immunotherapy (AIT) to desensitize patients by repeatedly exposing them to controlled doses of the allergen, thereby promoting immunological tolerance. Inmunotek provides this extract in various platforms, including the sublingual spray Oraltek and the subcutaneous alum-precipitated suspension Alunitek. The therapeutic goal is to modify the underlying allergic disease by inducing peripheral T-cell tolerance and shifting the immune response from a Th2-dominated allergic profile to a Th1/Treg-mediated profile.
- Brand names
- OraltekAlunitekBactek
- Other names
- Storage mite extractLepidoglyphus destructor allergen extract
02
Targets
A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)IL10 (Interleukin-10)IL-4 (Interleukin 4)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on lepidoglyphus destructor extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lepidoglyphus destructor extract.